Health & Wellness

The Health & Wellness Technology Cluster of TechVision provides end-to-end consulting services to help healthcare firms uncover emerging technologies.

The Health & Wellness (H&W) cluster‘s technology experts, are focused on understanding the myriad of disruptive innovations & trends impacting the global healthcare community. In this era of personalized medicine translating are translating years of research into novel disruptive technologies which are driving the global healthcare sector towards becoming increasingly patient centric.

Key Focus Areas


Research advances across biomarker platforms have fueled growing advances in companion diagnostics to enable optimization of therapy selection.


Targeted small molecule, protein and nucleic acid therapies with enhanced efficacy profiles and a decreased propensity of off-target effects are likely to drive the future of the global pharma industry.


Exponential rise in microbial research and growing industry interests are likely to empower microbiome based innovations across pharma, personal care and food sectors.


Considering that over half the world’s population lives in areas where the Aedes aegypti mosquito is present, there is mounting research for curbing the spread of infectious diseases such as Zika

Snapshot of Global Top 50 Technologies

Snapshot of Technology Capabilities

Our commitment to primary interviews ensures that you are not only updated about what has been productized today, but also the basic technology or academic research that will be the next-big-thing tomorrow.

Skin Wellness

Disruptive skincare innovations that leverage:

  1. Anti-aging
  2. Microbiome Science
  3. Genomics
  4. Skin Diagnostics
  5. E-skin Platforms


F&S tracks innovations across

  1. Immuno-oncology
  2. Biobetters
  3. Nucleic Acid Therapies
  4. Cell Therapies
  5. Monoclonal Antibodies

Life Sciences

The TechVision team has extensive technology expertise across the following areas:

  1. 3D cell culture systems
  2. Lab on a chip/organ on a chip


F&S tracks developments reshaping the CRO and CDMO landscapes, including tracking new trends across the following landscapes:

  1. Biomanufacturing
  2. Patient engagement
  3. Bioprocessing
  4. Bioreliance
  5. Biomonitoring


Diagnostics that are based on one or more of the following technologies:

  1. Genomics
  2. Proteomics
  3. Metabolomics
  4. Microbiomics
  5. Digital Biomarkers


Frost & Sullivan closely tracks pharma developments, which includes innovations in drug delivery platform. We have delivered bespoke consulting assignments related to drug repurposing and partnering for large pharma concerns.

A Global Biopharmaceutical Giant

Biopharmaceutical R&D Benchmarking Guide

The Challenge

Conduct a detailed assessment of the R&D and relevant business activities of top biopharmaceutical companies to garner an understanding of research and business-related strengths and weaknesses.

Provide recommendations to the client that will guide them during their annual strategic business planning across in target technology platforms, applications, and investments


  • Important parameters of the study included analysis of platforms, pipeline, financials, people/expertise and strategy
  • The project also involved benchmarking the R&D capabilities and strategies of the competing firms and develop a quantitative assessment of relative technological positioning of client versus their competitors.

Our Approach

Led by Frost & Sullivan’s VP of TechVision, based in New York, the team:

  • Established networks with SVP, VPs and Directors across top biopharmaceutical companies to understand under the radar developments.
  • Collated and assimilated primary data points across pertinent categories i.e. Strategy, Technology, and Emerging opportunities.
  • Developed a weight metric system to analyze qualitative information and arrive at a suitable comparative assessment.


The main deliverable was a Benchmarking and Competitive Intelligence Report, highlighted by an on-site client presentation with the following structure:

  • The client’s peers benchmarked and evaluated across multiple parameters
  • The overall pipeline database with in-depth information on all pipeline products
  • Interactive pipeline visualization platform on iFrost
  • Frost & Sullivan’s Recommended Approach
  • We also delivered an interactive iFrost platform during the client presentation, which enables continued access to growing database information.

A large FMCG Company

Microbiome to Consumer Benefits

The Challenge

Identify (and validate) an opportunity to leapfrog client’s involvement in Microbiome enabled innovation via M&A or 1-100 approach adding to health & wellness business within a short period span of six months.


  • Evaluation of the global microbiome landscape for OTC and other general products linked to Health/VMS/Hygiene
  • Linking ‘capabilities’ to a subsequent pool of ‘global players’ with commercialized products
  • Suggesting tangible ‘next steps’ under an existing or acquired brand

Our Approach

  • Frost & Sullivan conducted a comprehensive landscape assessment of the microbiome platform to identify technologies OTC and other general players as per project needs
  • We listed key and benchmarked technology segments and players within each segment
  • Mapped opportunities within the microbiome landscape to client’s key focus areas


Frost & Sullivan delivered an extensive microbiome landscape overview with strategic insights pertaining to partnerships and recommendations within this space.

  • A final slide deck (summary of findings in MS PowerPoint)
  • Presentation of the interim report and draft of final project report
  • Datasheets with the raw data used for the analysis in MS Excel
  • Frost & Sullivan’s recommended approach

A Top Ranking University in the USA

White Space Analysis, IP Perspectives

The Challenge

The client was interested in analyzing the white space pertaining to a given drug delivery process.


Evaluate the white space that exists for a particular form of drug delivery technology, such that the Client can venture and develop further with respect to technologies in the space which had little or no IP activity.

Our Approach

  • F&S assembled a team of subject matter experts (technical experts and patent analysts) to do the stated work.
  • Several parameters were ascertained with respect to which the white space was to be analyzed.
  • The entire portfolio (patent as well as non-patent literature) for the given technology was studied to understand the existing patenting activity in the given technology space.
  • The study of the existing IP activity threw light on the gaps that persist, where the Client can further act on for R&D.

Our Outcome

  • Analysis of the portfolio with respect to the pre-decided parameters.
  • The application areas of the given technology
  • The different manufacturing methods of the drug delivery system.
  • The different components that are used to develop the particular technology.
  • The various bioactive materials that can be delivered via this method.

Are YOU ready to embrace transformation?

Frost & Sullivan has six decades of experience analysing industry transformation and identifying innovative growth opportunities. Start your transformational journey that, fuelled by four powerful components, will ensure your success in navigating the ever-changing landscape of your industry.

Schedule a Growth Dialog with our team to dive deeper into transformational strategies and explore specific needs within your company.

Become a Frost Growth Expert in your area of specialization and share your expertise and passion with the community through our think tanks.

Join Frost & Sullivan’s Growth Council and gain access to leading global executives and think tanks focused on the transformational growth strategies of the mobility industry.

Designate your company as a Company to Action to increase exposure to investors, partnership potential, new M&A opportunities, and other growth prospects for your business.